Condition: Colorectal Cancer · Non-Small Cell Lung Cancer · Breast Cancer · Sponsor: Immunome, Inc.
This study will test the safety and effectiveness of a drug called IM-1617 in participants with solid tumors. Participants will have solid tumor cancer that has spread through the body (metastatic) or cannot be removed with surgery (unresectable). This study will have two parts. Part A will test increasing doses of IM-1617 to find out the safe dose and schedule of IM-1617 for participants. Part B will use the dose and schedule found in Part A to further study the safety of IM-1617 and if it works to treat solid tumor cancers.
This description comes directly from the study's public registry record.
Immunome Medical Monitor · 425.939.7410 · IM-1617-101@immunome.com
Always discuss trial participation with your own doctor first.
| Florida Cancer Specialists & Research Institute - Sarasota Cattlemen | Sarasota, Florida, United States | Recruiting |
| NEXT Dallas | Irving, Texas, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07578571